Loading…

Loading grant details…

Completed NON-SBIR/STTR RPGS NIH (US)

Robust immune tolerance conferred by Foxp3 transcriptional regulation

$4.49M USD

Funder NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Recipient Organization St. Jude Children'S Research Hospital
Country United States
Start Date Jan 20, 2021
End Date Dec 31, 2025
Duration 1,806 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10330039
Grant Description

Robust immune tolerance conferred by Foxp3 transcriptional regulation Regulatory T (Treg) cells actively suppress self-destructive T cells that cause a variety of autoimmune diseases. Despite significant progress, Treg-based treatment is significantly constrained by limited methods to improve Treg suppressive capacity. We aim to dissect the mechanistic processes of Treg induction and lineage

maintenance to uncover the factors and mechanisms conferring robust immune suppressive function. Treg cells are induced by the convergence of environmental cues delivered to differentiating T cells with considerable variations, resulting in stochastic Treg development. Besides, the DNA sequences of the genetic elements

regulating Treg lineage identity also vary among individuals. Given the enormously diverse T cell antigen receptors (TCRs) and target specificities, Treg cells are induced with many uncertainties. Once committed, Treg fate is maintained for extended suppressive function by cell-intrinsic and -extrinsic factors that constantly

fluctuate. All these uncertainties raise a question about how robust immune tolerance is conferred by Treg cells. Study of Treg master regulator Foxp3 offers a unique approach to address this question, because Foxp3 expression centers Treg fate determination and function. We hypothesize that an adequate buffering capacity

conferred by efficient Treg development and lineage stability opposes the genetic variations and immune perturbations. To test this hypothesis, we examined the Foxp3 enhancers that dictate Treg induction and lineage stability. Individual Foxp3 enhancers were known to play stage-specific roles in Foxp3 induction or maintenance.

However, mice bearing their individual mutations develop mild if any immune dysregulation despite significant defects in Treg development or lineage stability. To solve this mystery, we examined the epigenetic mechanisms mediating Foxp3 expression and hypothesize that Foxp3 enhancers coordinate to enable efficient Treg induction

or stable lineage identity for adequate Treg buffering capacity. We generated new mouse strains to test our hypotheses and found that deletion of two interacting Foxp3 enhancers caused fatal autoimmune diseases accompanied with severe defects of Treg induction or lineage stability. This result together with other studies delineates a full spectrum of Treg buffering capacity acquired

through coordinating Foxp3 enhancers. In the proposed study, we will fully uncover the immunological consequences of mice with severely reduced Treg induction or lineage stability. We will develop new algorithms and use single cell RNA sequencing to assess Treg repertoire diversity and lineage stability to infer Treg buffering

capacity. We will also use our newly developed mouse genetic tools to determine the role of continuous thymic Treg induction in maintaining the Treg buffering capacity. Overall, our study will uncover a full spectrum of Treg suppressive capacity conferred by Foxp3 transcriptional regulation. It will improve our basic understanding of Treg-related autoimmune diseases.

All Grantees

St. Jude Children'S Research Hospital

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant